We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02340208
Recruitment Status : Completed
First Posted : January 16, 2015
Last Update Posted : March 14, 2019
Pharm-Olam International
Information provided by (Responsible Party):
Helix BioPharma Corporation

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : August 1, 2017
Actual Study Completion Date : December 20, 2017